AMENDMENTS TO THE CLAIMS

The following listing of claims replaces, without prejudice, all prior versions and listings of claims in this application:

1-91. (Cancelled).

92. (Previously presented) A method of treating Huntington's disease in a human subject in need thereof comprising administering to the subject a therapeutically effective amount of a polypeptide comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4 and having cysteine residues at positions 7, 28, 59, 95, 148, 151, 161, 219, 243, and 265 relative to the amino acid sequence of SEQ ID NO: 4.

93-128. (Cancelled).

129. (Previously presented) The method of claim 92, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 4.

130-131. (Cancelled)

132. (New) A method of treating Huntington's Disease in a human subject in need thereof comprising administering to the subject a therapeutically effective amount of a polypeptide comprising an amino acid sequence:
- having at least 95% identity to the amino acid sequence of SEQ ID NO: 4;
- having cysteine residues at positions 7, 28, 59, 95, 148, 151, 161, 219, 243, and 265 relative to the amino acid sequence of SEQ ID NO:4; and
- having all amino acid residues marked in Figure 3a as fully conserved.

133. (New) The method of claim 132, wherein any mutation to an amino acid residue marked in Figure 3a as strongly conserved is made within the following conserved groups: serine,

threonine, and alanine; asparagines, glutamic acid, glutamine, and lysine; asparagine, histidine, glutamine, and lysine; asparagine, glutamic acid, aspartic acid, and glutamine; glutamine, histidine, arginine, and lysine; methionine, isoleucine, leucine, and valine; methionine, isoleucine, leucine, and phenylalanine; histidine and tyrosine; and phenylalanine, tyrosine, and tryptophan.